Clinical Trial Update: Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of a modified docetaxel-cisplatin-5-FU regimen with bevacizumab in unresectable or metastatic gastroesophageal adenocarcinoma completed; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• FLUOROURACIL (Fluorouracil)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Stomach Neoplasms, Esophageal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2016-03-14